12:00 AM
Jul 22, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Astellas sales and marketing update

Astellas launched Xtandi enzalutamide in the U.K. to treat metastatic castration-resistant prostate cancer (CRPC) in patients previously treated with docetaxel. The product is...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >